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ABSTRACT
Hepatocellular carcinoma (HCC), which accounts for 85–90% of primary liver 
cancer, is now the second leading cause of cancer-related mortality worldwide. Here 
we reported that Aldo-Keto Reductase family 7A isoform 3 (AKR7A3) is frequently 
down-regulated in HCC, associating with poor overall survival rate, elevated serum 
α-fetoprotein (AFP) and poor differentiation of HCC. The promoter region of AKR7A3 
was detected to be hypermethylated. Loss of heterozygosity (LOH) was also detected 
in AKR7A3. Functional assays on both AKR7A3 overexpressed and knockdown cells, 
including foci formation, colony formation in soft agar, migration, invasion and tumor 
formation in nude mice, demonstrated the strong tumor suppressive functions of 
AKR7A3. In addition, treatment of chemotherapy drug cisplatin showed that AKR7A3 
sensitizes tumor cells to apoptosis. Mechanistically, western blot analysis showed that 
overexpression of AKR7A3 inhibits the activation of ERK, c-Jun and NF-κB. In summary, 
we found that AKR7A3 functions as a tumor suppressor gene in HCC through attenuating 
c-Jun, ERK and NF-κB signaling pathways.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
frequently diagnosed malignancies with poor prognosis [1]. 
It is widely accepted that abnormal chromosomal changes, 
including amplification and deletion, greatly contribute to 
the onset of HCC [2]. Accumulation of genetic alterations 
may lead to constant activation of proto-oncogenes and 
inactivation of important tumor suppressor genes, resulting 
in abnormalities in cell functions such as cell proliferation 
and apoptosis [3]. In HCC, some specific chromosomal 
regions were found to be frequently deleted. These regions 
include 1p, 4q, 8p, 13q, 16q and 17p [4–5]. 
Aldo-Keto Reductase Family 7, Member A3 
(AKR7A3), which locates on chromosome 1p36, 
belongs to the aldo-keto reductases (AKRs) superfamily. 
This super family consists of 15 families with more 
than 140 members, which function to reduce aldehydes 
and ketones to alcohols [6]. These enzymes were also 
reported to play important roles in nuclear receptor 
signaling, cellular metabolism, inflammatory responses, 
osmoregulation, endobiotic and xenobiotic detoxification 
and hormone synthesis [6–7]. Accumulating evidence 
supported that AKR1 and AKR7 are involved in the 
development of cancers such as breast, lung, liver, 
colorectal and prostate cancers [8]. AKR7A3 is 
responsible for the detoxification of aflatoxin B1—a 
potent hepatocarcinogen [9]. In breast cancer, high 
expression level of AKR7A3 significantly associates 
with longer disease free survival [10]. 
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Here, we reported that AKR7A3 is frequently 
down-regulated in HCC tissues compared to adjacent non-
tumor tissues. Hypermethylation of promotor regions and 
chromosome deletion are found to be responsible for the 
down-regulation of AKR7A3. Clinically, low AKR7A3 
expression is associated with poor overall survival, 
elevated serum AFP and poor differentiation of HCC 
tissue, indicating the important role of AKR7A3 in the 
suppression of HCC. In vitro functional studies, including 
foci formation, colony formation in soft agar, migration 
and invasion, revealed strong tumor suppressive functions 
of AKR7A3. In vivo tumor formation experiments in nude 
mice also demonstrated the inhibition of tumor formation 
by AKR7A3 overexpression. Downstream factors of 
EMT markers and signaling pathways crucial in cancer 
development including ERK, c-Jun and NF-κB were also 
detected. Western blot results demonstrated that AKR7A3 
could inhibit the phosphorylation of ERK, c-Jun and NF-κB 
in HCC cell lines.
RESULTS
The clinical significance of AKR7A3
Three pairs of primary HCC tumor samples and 
adjacent non-tumor tissues were subjected to transcriptome 
sequencing. Sequencing data revealed that AKR7A3 was 
among the 102 genes that were down-regulated in all the 3 
HCC samples, as compared to paired non-tumor samples. To 
detect the expression level of AKR7A3 in a larger cohort of 
HCC samples, qRT-PCR was performed on 129 pairs of HCC 
patient samples. Results showed AKR7A3 was significantly 
down-regulated in HCC (***P = 0.0009) (Figure 1A). In 50 
out of 129 tested sample pairs, AKR7A3 was detected with 
more than 2 folds of down-regulation. Western blot analysis 
on 10 pairs of HCC samples also supported the above results, 
where AKR7A3 expression significantly reduced in HCC 
tissues (Supplementary Figure S1). The down-regulation of 
AKR7A3 was also significantly associated with poor overall 
survival rate (*P = 0.031) (Figure 1B), elevated serum AFP 
level (***P < 0.001) (Table 1) and poor differentiation of 
HCC (*P = 0.011) (Table 1).
Promotor hypermethylation and allele loss 
contribute to AKR7A3 down-regulation in HCC
Epigenetic alternations, including promoter 
hypermethylation, is one of the most frequent causes of 
gene down-regulation [11]. In order to investigate the 
reasons behind AKR7A3 down-regulation, the methylation 
status of AKR7A3 promotor region was studied. A 
536 bp CpG island within the AKR7A3 promoter region 
containing 60 CpG sites was predicted using MethPrimer 
software (Figure 2A). Primers were designed to amplify 
this region from the bisulfite treated DNA of HCC 3 
cell lines and one pair of HCC primary samples. In cell 
line samples, endogenous AKR7A3 expression was first 
detected by qRT-PCR (Supplementary Figure S2), followed 
by BGS analysis, which results showed that the methylation 
frequency was significantly higher in HCC cell line with 
low AKR7A3 expression (QGY7703 and PLC8024) than 
that in the cell line with high AKR7A3 expression (H2M) 
(Figure 2B). In paired HCC samples (274N and 274T), 
where AKR7A3 was down-regulated by more than 100 
folds in tumor tissue, the promotor region of AKR7A3 was 
found to be hypermethylated in tumor tissue, as compared 
to adjacent non-tumor tissue (Figure 2B).
MSP was subsequently performed to detect the 
methylation status in a larger amount of samples. Our 
results showed that methylated allele was more prominent 
in AKR7A3 low-expressing cell lines (Huh7, HepG2, 
BEL7402, QGY7703 and PLC8024), while unmethylated 
allele was more prominent in AKR7A3 high-expressing 
cell lines (97L and H2M) (Figure 2C, upper panel). 
Analysis on 79 HCC DNA detected methylated allele 
in 33/79 (52%) of HCC cases (Table 2). The frequency 
of AKR7A3 promoter hypermethylation with AKR7A3 
down-regulation was significantly higher (16/21, 76%) 
than that in HCC cases without down-regulation 
(*P = 0.011) (Table 2). Representative images of six 
paired HCC samples with AKR7A3 down-regulation 
showed higher prominence of methylated allele in tumor 
samples and unmethylated allele in non-tumor samples 
(Figure 2C, lower panel). 
To further evaluate whether AKR7A3 down-
regulation is directly affected by the methylation of 
AKR7A3 promoter, three HCC cell lines with low 
(QGY7703 and PLC8024) and high (H2M) AKR7A3 
expression were treated with gradient concentrations 
of demethylating agent 5-azacytidine (5-aza-dC). After 
treatment, AKR7A3 expression was detected by qRT-
PCR. Results showed that 5-aza-dC treatment successfully 
restored AKR7A3 expression in both cell lines with 
promoter hypermethylation (QGY7703 and PLC8024) 
but not in the cell line without promoter hypermethylation 
(H2M) (Figure 2D). 
In HCC, chromosome 1p is frequently detected 
with chromosome material loss [5]. Our transcriptome 
sequencing data revealed 19 down-regulated genes that 
are located on chromosome 1p, AKR7A3 being one of 
them. The fact that AKR7A3 locates in this region leads 
us to look into whether chromosome loss plays a role in 
the down-regulation of AKR7A3. To test this hypothesis, 
two sets of primers flanking 2 SNP positions (rs1738025 
and rs2231198, located on exon 2 and exon 6 of AKR7A3, 
respectively) were designed to amplify two regions 
within AKR7A3 coding sequence. The PCR product was 
sequenced and dual peaks at either one of the two SNPs 
were found in 55 out of 85 of the tested non-tumor DNA 
samples (Figure 2E). Among these 55 samples, 30 showed 
AKR7A3 down-regulation and 13 of them were detected 
with allele loss, demonstrated by LOH of tumor DNA 
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samples (Table 3). The AKR7A3 expression levels were 
further compared between HCC cases with and without 
LOH. The relative down-regulation of AKR7A3 in HCC 
samples with LOH was significantly more aggravated than 
that without LOH (*P < 0.05) (Figure 2F). These results 
demonstrated the important role of chromosome deletion 
in the down-regulation of AKR7A3.
AKR7A3 demonstrated strong tumor 
suppressive functions
In order to study the tumor suppressive functions 
of AKR7A3 in HCC, the CDS sequence of this gene was 
cloned into a lentiviral vector. Cells transfected with empty 
vector were used as controls. Blasticidin was applied to the 
transfected cells to screen for two stably transfected cells 
in two cell lines (QGY7703 and PLC8024) with relatively 
low endogenous AKR7A3 expression (Supplementary 
Figure S2). For each cell line, two clones with highly 
expressed AKR7A3 were selected for further studies 
(Figure 3A). The tumor suppressive functions of AKR7A3 
in vitro were investigated by foci formation, soft agar, 
migration and invasion assays. In cells transfected with 
AKR7A3, significantly lower number of foci formed (*P 
< 0.05; **P < 0.01) (Figure 3B) and colonies formed in 
soft agar (**P < 0.01; ***P < 0.001) (Figure 3C) were 
detected, as compared with control cells. In migration and 
invasion assays, AKR7A3 transfected cells demonstrated 
significantly lower ability to migrate (*P < 0.05) 
(Figure 3D) and invade (*P < 0.05; **P < 0.01) 
(Figure 3E). We further validated AKR7A3 functions 
through in vivo tumor formation assay in nude mice. 
PLC8024-AKR7A3 and control cells were subcutaneously 
injected into the right and left dorsal flanks of 5 nude mice, 
respectively. PLC8024-AKR7A3 could not form tumor in 
any of the 5 mice, whereas PLC8024-vector cells formed 
tumor in all mice in the experiment (Figure 3F).
AKR7A3 knockdown enhances oncogenicity of 
HCC
To further access the effect of AKR7A3 down-
regulation, two HCC cell lines (H2M, 97L) with 
relatively high endogenous AKR7A3 expression was 
stably transfected with two short hairpin RNAs (shRNA) 
targeting AKR7A3. The knockdown of AKR7A3 was 
confirmed by western blot (Figure 4A). Vector cloned with 
scrambled shRNA was used as control. In foci formation 
and soft agar assays, AKR7A3 knockdown cells formed 
significantly higher numbers of colonies, as compared to 
control cells (*P < 0.05; **P < 0.01; ***P < 0.001) (Figure 
4B and 4C). AKR7A3 knockdown cells also showed 
stronger abilities to migrate (*P < 0.05; **P < 0.01) 
(Figure 4D) and invade (*P < 0.05) (Figure 4E). 
AKR7A3 inhibits chemoresistance of HCC
To investigate the effects of AKR7A3 on 
chemoresistance in HCC, cisplatin—a chemotherapeutic 
drug—was used to treat 8024-AKR7A3 and H2M-sh3 
cells together with their respective control cells. Cell 
viability assay (XTT) was performed on cells treated with 
gradient concentrations of cisplatin and vehicle control. 
Results showed that AKR7A3 overexpressed cells are 
more prone to apoptosis upon cisplatin treatment (*P < 
0.05; **P < 0.01; ***P < 0.001) (Figure 5A), whereas 
AKR7A3 knockdown cells are more chemoresistant 
(*P < 0.05; **P < 0.01) (Figure 5B).
Figure 1: AKR7A3 is frequently down-regulated in HCC with clinical significance. (A) Expression level of AKR7A3 in 129 
pairs of HCC tumor and adjacent non-tumor samples detected by qRT-PCR. ***P = 0.0009. (B) Overall survival rate of AKR7A3 normal 
expression (+) and low expression (−) patients. *P = 0.031.
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AKR7A3 exerts tumor suppressive effects 
through attenuating ERK, c-Jun and NF-κB 
signaling pathways
In light of the confirmation of the tumor suppressive 
abilities of AKR7A3, the downstream signaling pathways 
were studied. Cell lysates of 8024-AKR7A3 and 
7703-AKR7A3 along with their empty vector controls were 
harvested and subjected to western blot analysis. In both cell 
lines, the expression of two of the epithelial–mesenchymal 
transition (EMT) markers, including fibronectin and Snail, 
were detected to be inhibited by AKR7A3 overexpression 
(Figure 5C), which could partly explain the effects of 
AKR7A3 overexpression on migration and invasion of 
HCC cells. Overexpression of AKR7A3 was further shown 
to attenuate three important signaling pathways controlling 
liver cancer development, including ERK, c-Jun and NF-κB 
signaling pathways, as demonstrated by the significant lower 
levels of p-ERK, p-c-Jun and p-NF-κB levels in AKR7A3 
overexpressed cells than that in the control cells (Figure 5C).
Table 1: Association of AKR7A3 down-regulation with clinicopathological features in 129 primary 
HCCs
Features Total
AKR7A3 expression
P value 
Normal expression Down-regulation
Gender  
Male 106 68 (64.2%) 38 (35.9%)
Female 23 11 (47.8%) 12 (52.2%) 0.162
Age  
≤ 60 105 61 (58.1%) 44 (41.9%)
> 60 24 18 (75%) 6 (25%) 0.165
Hepatitis B surface antigen*  
Positive 96 57 (59.4%) 39 (40.6%)
Negative 25 19 (76%) 6 (24%) 0.165
Serum α-fetoprotein level (ng/ml)  
< = 400 64 50 (78.1%) 14 (21.9%)
> 400 56 25 (44.6%) 31 (55.4%) < 0.001
Cirrhosis  
Present 85 55 (64.7%) 30 (35.3%)
Absent 36 21 (58.3%) 15 (41.7%) 0.541
Tumor stage  
Stage I 86 54 (62.8%) 32 (37.2%)
Stage II 5 3 (60%) 2 (40%)
Stage III 30 17 (56.7%) 13 (43.3%) 0.838
Tumor size  
< 5 cm 38 20 (52.6%) 18 (47.4%)
> 5 cm 85 56 (65.9%) 29 (34.1%) 0.228
Differentiation  
Well differentiated (I-II) 66 49 (74.2%) 17 (25.8%)
Moderately differentiated (II-III) 44 21  (47.7%)  23 (52.3%)
Poorly differentiated (III-IV) 3 1 (33.3%) 2 (66.7%) 0.011
Metastasis  
Positive 59 37 (62.7%) 22 (37.3%)
Negative 70 42 (60%) 28 (40%) 0.856
*Partial data was not available, and the statistical analysis was based on available data. 
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DISCUSSION
Hepatocellular carcinoma has long been considered one 
of the most lethal cancers worldwide with poor prognosis [1]. 
The elucidation of the genetic causes of HCC onset and 
progression has always been extensively pursued but is still 
far from complete. AKR7A3 is one of the key enzymes in 
the reduction of aflatoxin B1, a strong hepatocarcinogen [9]. 
There are mounting evidence supporting the critical function 
of this gene in normal liver processes.
Figure 2: Promoter hypermethylation and LOH of AKR7A3 were observed in HCC. (A) A CpG island (−307 to +229) of 536 
bp covering 60 CpG sites were predicted by software MethPrimer. BGS and MSP regions are indicated. (B) Methylation status of promoter 
region of AKR7A3. The areas of black regions within each circle indicate the percentage of colonies with the specific CpG site methylated. 
HCC cell lines of low (QGY7703 and PLC8024) and high (H2M) AKR7A3 expression, as well as paired human HCC tissue samples, 
including non-tumor and tumor samples, were examined. (C) Methylation-specific PCR results of HCC cell lines and clinical samples. DNA 
extracted from cell lines and clinical samples were detected by MSP using methylation-specific primers (M: methylated; U: unmethylated). 
(D) The expression level of AKR7A3 in cell lines with low (QGY7703 and PLC8024) or high (H2M) AKR7A3 expression after 50 uM 
or 100 uM of 5-Aza-dC and vehicle control treatment. (E) Representative images showing DNA samples with LOH, indicated by the 
presence of SNP dual peaks in non-tumor samples (449N, 278N) and single peaks in tumor samples (449T, 278T) at 2 SNP (rs2231198 and 
rs1738025) positions. (F) Comparison of fold change of AKR7A3 expression between patient samples with or without LOH. *P < 0.05.
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Here, we reported that AKR7A3 acts as a potent 
tumor suppressor in hepatocellular carcinoma. AKR7A3 
was not only found to be frequently down-regulated 
in HCC (Figure 1A), but also demonstrated strong 
clinical significance. The association between AKR7A3 
expression and overall survival rate of HCC patients 
indicated the importance of AKR7A3 in preventing HCC 
onset and progression. Our data also showed the lower 
AKR7A3 expression being correlated with elevated serum 
AFP level, assuring the potential of AKR7A3 as a marker 
for HCC prediction and diagnosis.
Bisulfite genomic sequencing and methylation-
specific PCR revealed promotor hypermethylation of 
AKR7A3, which partly explains the AKR7A3 down-
regulation in HCC. Our data showed that the promoter 
region of AKR7A3 low expression cell lines (QGY7703 
and PLC8024) were much more severely methylated 
than those of AKR7A3 high expression cell lines 
(97L and H2M) (Figure 2B and 2C). Chromosome 1p 
has been found to frequently harbor deletions of genetic 
materials in HCC [5]. AKR7A3 being located in this 
region hints deletion of this gene in HCC, which gives rise 
to its down-regulation. Loss of heterozygosity analysis on 
HCC patient DNA samples revealed the frequent deletion 
of AKR7A3, indicated by the high percentage of patients 
having allele loss in HCC tissue (43% of AKR7A3 down-
regulated HCC samples showed LOH; Table 3).
The tumor suppressive functions of AKR7A3 were 
explored both in vitro and in vivo. Foci formation and 
soft agar assays determine the abilities of cells to grow 
into colonies under anchorage-dependent and anchorage-
independent conditions, respectively. In both assays, 
AKR7A3 overexpression strongly inhibited colony 
growth, while AKR7A3 knockdown promoted colony 
formation. For migration and invasion abilities, AKR7A3 
overexpressed cells migrated and invaded in much slower 
manners, while AKR7A3 knockdown cells migrated and 
invaded faster (Figure 4D and 4E). For in vivo tumor 
formation assay, PLC8024 cell line overexpressed with 
AKR7A3 could not form tumor subcutaneously, while 
control cells all formed tumors (Figure 3F). The effect of 
AKR7A3 on the chemoresistance of HCC was also tested. 
AKR7A3 overexpressed and control cells were treated 
with cisplatin and cell viability assay was performed. Cells 
overexpressed with AKR7A3 demonstrated much lower 
chemoresistence than control cells (Figure 5A). All of the 
above assays supported our assumption that AKR7A3 
strongly suppresses the oncogenic abilities of cancer cells.
In order to understand the underlying mechanisms 
of AKR7A3 tumor suppressive effects, the activity of 
certain important signaling pathways in liver cancer 
development, including MAPK, c-Jun and NF-κB, were 
detected by western blot. ERK1 and ERK2 were found 
to be constitutively activated in various types of human 
tumor tissues [12]. They play pivotal roles in promoting 
cell proliferation and metastasis in human cancers [13]. 
Our data showed that AKR7A3 potently inactivates ERK 
phosphorylation, which could in part explain the strong 
tumor suppressive effects of AKR7A3. c-Jun is a proto-
oncogene and a transcription factor. It has been reported 
that c-Jun protects hepatocytes from apoptosis through 
antagonizing p53 functions [14]. NF-κB is a protein 
complex that expresses extensively in animal cell types. In 
many types of cancers, NF-κB activates the transcription 
of anti-apoptotic proteins, leading to uncontrolled cell 
proliferation and tumor growth [15]. We found that 
AKR7A3 overexpressed cells have lower c-Jun and NF-κB 
activities, which could explain our data of AKR7A3 
Table 2: The correlation between AKR7A3 methylation and expression level of AKR7A3 in HCC 
patients
AKR7A3 down-regulation
Total P value
Absent Present
AKR7A3 promoter Absent 33 (57%) 25 (43%) 58 (73%) 0.011
methylation Present 5 (24%) 16 (76%) 21 (27%)
Total 46 (48%) 33 (52%) 79
Table 3: The correlation between LOH status and expression level of AKR7A3 in HCC patients
LOH at AKR7A3 region
Total P value
Absent Present
AKR7A3 expression
Normal 20 (80%) 5 (20%) 25 (45%) 0.087
Down-regulated 17 (57%) 13 (43%) 30 (55%)
Total 37 (67%) 18 (33%) 55
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Figure 3: AKR7A3 demonstrated strong tumor suppressive functions. (A) Western blot showing successful overexpression 
of AKR7A3 in QGY7703 and PLC8024 cell lines. β-actin was used as loading control. (B) Representative images and quantification of 
number of foci formed by QGY7703 and PLC8024 vector and AKR7A3 transfected cells. *P < 0.05, **P < 0.01. (C) Representative images 
and quantification of number of colonies formed in soft agar assay by QGY7703 and PLC8024 vector and AKR7A3 transfected cells. 
**P < 0.01, ***P < 0.001. (D) Representative images and quantification of migrated cells and (E) invaded cells of QGY7703 and PLC8024 
vector and AKR7A3 transfected cells. *P < 0.05, **P < 0.01. (F) Representative image and quantification of in vivo tumor formation assay 
of PLC8024 vector and AKR7A3 transfected cells on nude mice.
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Figure 4: Knockdown of AKR7A3 induced tumorogenicity characteristics of HCC cell lines. (A) Western blot showing 
successful knockdown of AKR7A3 in H2M and 97L cell lines. β-actin was used as loading control. (B) Representative images and 
quantification of foci formed by H2M and 97L vector and shRNA transfected cells. **P < 0.01, ***P < 0.001. (C) Representative images 
and quantification of colonies formed in soft agar assay by H2M and 97L vector and shRNA transfected cells. *P < 0.05, **P < 0.01. 
(D) Representative images and quantification of migrated and (E) invaded cells of H2M and 97L vector and shRNA transfected cells. 
*P < 0.05, **P < 0.01.
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antagonizing cell growth and sensitizing HCC cells to 
chemotherapy drugs. 
Collectively, our data demonstrated frequent down-
regulation and clinical significance of AKR7A3 in HCC, 
as well as its strong tumor suppressive functions and 
inhibition of chemoresistance, which could be attributed 
to the attenuation of ERK, c-Jun and NF-κB signaling 
pathways. This report is the first to demonstrate the 
tumor suppressive functions of AKR7A3 in HCC, which 
gene was rarely studied in human cancers. The strong 
suppression of ERK, c-Jun and NF-κB signaling pathways 
by AKR7A3 reflects the multiple and complex molecular 
inhibition effects of this gene on the development and 
progression of HCC. This finding will provide new insight 
into the pathogenesis of HCC, potentially help develop 
new therapeutic strategies against this lethal disease.
MATERIALS AND METHODS
Clinical HCC tissue samples and cell lines
Clinical HCC tumor and adjacent non-tumor tissues 
were collected from Sun Yat-Sen University Cancer 
Center (Guangzhou, China). All HCC patients gave 
written informed consent on the use of clinical specimens 
for medical research. The collection of human tissues 
was approved by the Committees for Ethical Review 
of research involving human subjects of Sun Yat-Sen 
University (Guangzhou, China) and the Institutional 
Review Board of the University of Hong Kong. 
Immortalized human liver cell line (LO2) and HCC 
cell lines (QSG7701, BEL7402, QGY7703, PLC8024, 
HepG2 and Huh7) were obtained from the Institute of 
Virology, Chinese Academy of Medical Sciences (Beijing, 
China). MHCC-97L was obtained from the Liver Cancer 
Institute of Fudan University (Shanghai, China). H2M was 
previously established in our laboratory. The 293FT cell 
line was purchased from Invitrogen. All cell lines used in 
this study were regularly authenticated by morphological 
observation.
Bisulfite genomic sequencing (BGS) and 
methylation-specific PCR (MSP)
Genomic DNA was extracted and followed by bisulfite 
treatments using EpiTECT Bisulfite Kit (Qiagen). The CpG 
islands of AKR7A3 were predicted using software online 
(MethPrimer v1.1 beta, Li Lab, Department of Urology, 
Figure 5: AKR7A3 overexpressed cells are more sensitive to cisplatin and showed lower activity of ERK, c-Jun and 
NF-κB. (A) Cell viability assay of PLC8024 vector or AKR7A3 overexpressed cells after treatment by gradient concentrations of cisplatin. 
*P < 0.05, **P < 0.01, ***P < 0.001. (B) Cell viability assay of 97L control or shRNA transfected cells after treatment by gradient 
concentrations of cisplatin. *P < 0.05, **P < 0.01. (C) Western blot analysis of downstream factors on QGY7703 and PLC8024 vector 
and AKR7A3 transfected cells. EMT markers include fibronectin and Snail. Signaling pathways include c-Jun, NF-κB and ERK pathways, 
as demonstrated by down-regulated p-c-Jun, p-NF-κB and p-ERK in AKR7A3 overexpressed cells. β-actin was used as loading control.
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USCF). Primers were designed for PCR amplification 
of chosen CpG islands. Primer specificity was examined 
by DNA gel electrophoresis. The PCR products were 
subsequently cloned into pMD18-T vector and transformed 
into DH5α competent cells. 5 to 10 colonies were randomly 
picked and sequenced. MSP was used to test the methylation 
status of CpG islands on a larger cohort of samples. Primers 
were designed based on the sequencing results above and 
validated by DNA gel electrophoresis. Sequences of primers 
were listed in Supplementary Table S1.
Loss of heterozygosity analysis
Primers flanking two SNP positions (rs1738025 and 
rs2231198) were designed for amplifying DNA sequences 
of around 800 bp. PCR products were subjected to 
sequencing. The absence of dual peaks in tumor samples 
whose paired non-tumor sample harbors dual peak at SNP 
positions were considered LOH samples.
AKR7A3 overexpression and knockdown
The coding region sequence of AKR7A3 was 
amplified by PCR and cloned into pLenti6/V5-TOPO vector 
(Invitrogen). Empty vector or AKR7A3 constructs were 
co-transfected with the ViraPower Lentiviral packaging 
plasmids (Invitrogen) into 293FT cells. Supernatant 
containing lentivirus was added to QGY7703 and PLC8024 
cells. Blasticidin (Invitrogen) was added to the cells for 
screening for stably transduced cells after 24 hours.
For knockdown of AKR7A3, plasmids of two short 
hairpin RNAs targeting AKR7A3 and scrambled control 
were purchased from GeneCopoeia (Rockville). These 
plasmids were packed into virus and transduced into 
MHCC-97L and H2M cell lines. Puromycin was used to 
screen for stably transfected cells.
Quantitative real-time PCR
Total RNA of cell lines and clinical HCC tissues 
were isolated using TRIzol reagent (Invitrogen). 
Complementary DNA was synthesized using PrimeScript 
RT Master Mix (Takara). The expression levels of genes 
were detected with SYBR Green PCR Kit (Roche) using 
ABI Prism 7900 System. Specificity of primers were 
validated by DNA gel electrophoresis. Primer efficiency 
and sensitivity were further tested and validated by standard 
curves and melt curves in qRT-PCR. Sequences of the 
respective primers were listed in Supplementary Table S1. 
Relative expression differences were calculated using the 
2−ΔΔCt method. 18s was used as endogenous control.
In vitro and in vivo tumorigenicity functional 
assays
Foci formation assays were conducted by seeding 
1000 cells/well in a 6-well plate in triplicates and colonies 
were counted after 2 to 3 weeks. In soft agar assay, 
5000 cells/well were suspended in 0.35% agarose in 
DMEM/10% FBS in 6-well plates as the upper layer, with 
0.5% agarose in DMEM/10% FBS being the bottom layer. 
Cells in agarose were allowed to grow for 2 to 3 weeks and 
the numbers of colonies formed in each well were counted. 
In migration and invasion assays, cells were seeded in cell 
culture inserts or invasion chambers in serum free DMEM 
medium, with the bottom of the chambers immersed in 
DMEM/10% FBS. After 48 to 72 hours, migrated or 
invaded cell were counted under microscope. For in vivo 
tumor formation assay, PLC8024-AKR7A3 and control 
cells were subcutaneously injected into the right and left 
dorsal flanks of 5 nude mice. Tumor sizes were monitored. 
All animal procedures were approved by Committee 
on the Use of Live Animals in Teaching and Research 
(CULATR), the University of Hong Kong.
Cisplatin treatment and cell viability assay
For chemotherapy-induced cytotoxicity, 5000 cells/
well were seeded in 96-well plates and treated with 
cisplatin for 48 hours. Cell viability was measured by 
XTT. The percentage of viable cells was determined 
using the following formula: cell viability (%) = A492/630 of 
treated cells / A492/630 of control cells.
Western blot
Protein samples were denatured and separated in 
SDS-PAGE gel and transferred to PVDF membranes. 
The membranes were blocked with 5% non-fat milk 
and incubated with primary antibodies at 4°C overnight 
and HRP-conjugated secondary antibodies for 1 hour at 
room temperature. The chemiluminescence signals were 
visualized by exposing the ECL-incubated membranes to 
X-ray films.
Statistical analysis
Statistical analysis was performed by using SPSS 
version 20.0 (SPSS, Inc.) and GraphPad Prism 5.0 
(GraphPad Software, Inc.). Independent Student’s t-test 
was applied to compare the mean values of two groups. 
Error bars represent SD values. The clinicopathological 
features in patients with and without AKR7A3 down-
regulation were compared using Pearson’s chi-square test 
for categorical variables. Kaplan-Meier plots and Log Rank 
tests were used for overall survival and disease-free survival 
analysis. Statistical significance was defined as P ≤ 0.05. 
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